Down regulation of fatty acid synthase via inhibition of PI3K/AKT/mTOR in ovarian cancer cell line by novel organoselenium pseudopeptide

Overcoming drug resistance in ovarian cancer through PI3K/AKT signaling inhibitors

Ovarian cancer has been identified as the eighth most typical gynaecological malignancy and cause of health problems in women. For almost forty years, platinum doublet chemotherapy has usually been the cornerstone of first-line treatment regimens. The effectiveness of conventional chemotherapy is severely hampered by relapse rates and mortality from chemotherapy resistance, which lead to the spread and recurrence of malignant cancers as well as poor outcomes in terms of quality of life in patients. Drug resistance has been linked to several mechanisms, including increased drug efflux, decreased apoptosis, increased autophagy, and changed drug metabolism. Further, the dysregulation of tumor suppressors or oncogenes plays a crucial role in chemoresistance. Additionally, PI3K/AKT/mTOR signaling has been implicated in several in vitro as well as clinical studies as a significant contributor to chemotherapy resistance in case of ovarian cancer. This review discusses the potential of various crude extracts, synthetic molecules, and nanoformulations for targeting PI3K/AKT/mTOR pathway. Moreover, a range of clinical studies involving PI3K/AKT/mTOR inhibitors have been summed up, addressing both the promises and complexities associated with their use. Overall, the review aims to provide a roadmap for future investigations that could lead to improved therapeutic outcomes for patients suffering from ovarian cancer, emphasizing the urgent need for continued exploration of novel pathways and strategies to combat drug resistance.

The implications of FASN in immune cell biology and related diseases

Fatty acid metabolism, particularly fatty acid synthesis, is a very important cellular physiological process in which nutrients are used for energy storage and biofilm synthesis. As a key enzyme in the fatty acid metabolism, fatty acid synthase (FASN) is receiving increasing attention. Although previous studies on FASN have mainly focused on various malignancies, many studies have recently reported that FASN regulates the survival, differentiation, and function of various immune cells, and subsequently participates in the occurrence and development of immune-related diseases. However, few studies to date systematically summarized the function and molecular mechanisms of FASN in immune cell biology and related diseases. In this review, we discuss the regulatory effect of FASN on immune cells, and the progress in research on the implications of FASN in immune-related diseases. Understanding the function of FASN in immune cell biology and related diseases can offer insights into novel treatment strategies for clinical diseases.

The Ubiquitin-Proteasome System in Tumor Metabolism

Metabolic reprogramming, which is considered a hallmark of cancer, can maintain the homeostasis of the tumor environment and promote the proliferation, survival, and metastasis of cancer cells. For instance, increased glucose uptake and high glucose consumption, known as the "Warburg effect," play an essential part in tumor metabolic reprogramming. In addition, fatty acids are harnessed to satisfy the increased requirement for the phospholipid components of biological membranes and energy. Moreover, the anabolism/catabolism of amino acids, such as glutamine, cystine, and serine, provides nitrogen donors for biosynthesis processes, development of the tumor inflammatory environment, and signal transduction. The ubiquitin-proteasome system (UPS) has been widely reported to be involved in various cellular biological activities. A potential role of UPS in the metabolic regulation of tumor cells has also been reported, but the specific regulatory mechanism has not been elucidated. Here, we review the role of ubiquitination and deubiquitination modification on major metabolic enzymes and important signaling pathways in tumor metabolism to inspire new strategies for the clinical treatment of cancer.